Integra LifeSciences has received US regulatory clearance to market its Integra Titan Reverse Shoulder System, which offers greater flexibility for shoulder replacement surgery.
The company plans to begin a limited market release in the US in the third quarter of 2013, and globally following CE Mark clearance in Europe.
It is built on platform stem that simplifies the conversion of a primary total shoulder, or hemi for fracture, to a reverse shoulder, without the need to remove a stem well-fixed in a patient’s bone.
The system provides fully interchangeable components, enabling all primary, reverse, and fracture humeral bodies to be used with either the press-fit or cemented stems.
This flexibility offers surgeons to custom fit the prosthesis with minimally invasive intraoperative options to the unique anatomy of each of patient.
Integra LifeSciences president extremity reconstruction Robert Paltridge noted the company is excited in adding reverse shoulder system to its existing shoulder portfolio.
"The patient and surgeon benefits built into our new platform-based system are a true testimony to our continued investment in advancing cost-effective technology in shoulder surgery," Paltridge added.
Integra LifeSciences offers solutions in orthopaedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery.